Kopp Investment Advisors LLC decreased its position in NeoGenomics, Inc. (NASDAQ:NEO) by 10.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 406,444 shares of the medical research company’s stock after selling 47,904 shares during the quarter. NeoGenomics accounts for approximately 3.6% of Kopp Investment Advisors LLC’s holdings, making the stock its 6th largest position. Kopp Investment Advisors LLC’s holdings in NeoGenomics were worth $3,601,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. GSA Capital Partners LLP acquired a new position in shares of NeoGenomics in the 3rd quarter worth approximately $369,000. Bank of New York Mellon Corp grew its position in shares of NeoGenomics by 4.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 982,560 shares of the medical research company’s stock worth $10,935,000 after acquiring an additional 38,776 shares in the last quarter. Emerald Advisers Inc. PA grew its position in shares of NeoGenomics by 3.1% in the 4th quarter. Emerald Advisers Inc. PA now owns 1,424,263 shares of the medical research company’s stock worth $12,619,000 after acquiring an additional 42,790 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of NeoGenomics by 79.2% in the 2nd quarter. Goldman Sachs Group Inc. now owns 30,678 shares of the medical research company’s stock worth $275,000 after acquiring an additional 13,561 shares in the last quarter. Finally, Janus Henderson Group PLC grew its position in shares of NeoGenomics by 50.3% in the 3rd quarter. Janus Henderson Group PLC now owns 3,464,655 shares of the medical research company’s stock worth $38,562,000 after acquiring an additional 1,159,888 shares in the last quarter. Institutional investors own 84.72% of the company’s stock.
Shares of NeoGenomics, Inc. (NEO) opened at $8.71 on Monday. The stock has a market capitalization of $700.37, a P/E ratio of 145.17, a P/E/G ratio of 4.84 and a beta of 0.47. NeoGenomics, Inc. has a 1-year low of $7.08 and a 1-year high of $11.63. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.14 and a quick ratio of 1.99.
NEO has been the subject of several research reports. Zacks Investment Research upgraded NeoGenomics from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st. BidaskClub downgraded NeoGenomics from a “hold” rating to a “sell” rating in a report on Thursday, January 18th. Scotiabank set a $22.00 price target on NeoGenomics and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. CIBC set a $19.00 price target on NeoGenomics and gave the stock a “neutral” rating in a report on Wednesday, January 3rd. Finally, Royal Bank of Canada set a $23.00 price target on NeoGenomics and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company’s stock. NeoGenomics currently has a consensus rating of “Hold” and a consensus target price of $15.83.
COPYRIGHT VIOLATION NOTICE: “Kopp Investment Advisors LLC Has $3.60 Million Stake in NeoGenomics, Inc. (NEO)” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://sportsperspectives.com/2018/03/12/kopp-investment-advisors-llc-has-3-60-million-stake-in-neogenomics-inc-neo.html.
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.